Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.

Saved in:
Bibliographic Details
Title: Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy.
Authors: Campone, M.1,2, Bondarenko, I.3, Brincat, S.4, Hotko, Y.5, Munster, P. N.6, Chmielowska, E.7, Fumoleau, P.8, Ward, R.9, Bardy-Bouxin, N.10, Leip, E.11, Turnbull, K.11, Zacharchuk, C.11, Epstein, R. J.12
Source: Annals of Oncology. Mar2012, Vol. 23 Issue 3, p610-617. 8p. 1 Diagram, 3 Charts, 4 Graphs.
Database: Academic Search Ultimate
Description
ISSN:09237534
DOI:10.1093/annonc/mdr261